Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial

Further Publications

Differential Clinical and Immunological Impacts of Anti-T-Lymphocyte Globulin (ATLG) vs. Anti-Thymocyte Globulin (ATG) in Preventing Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation: A Comparative Study

Am J Hematol

Notarantonio AB, Morisset S, Piucco R, Pérès M, Boulangé L, Alitcher A, Brouard J, Monchablon L, Campidelli A, El Ouahabi S, Guisnel C, Moulin C, Kicki C, Roth-Guepin G, Feugier P, Bittencourt MC, Aarnink A, D'Aveni-Piney M, Hergalant S, Pagliuca S, Rubio MT

doi: 10.1002/ajh.27619

Multiple Myeloma (MM)

Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial

Lancet Haematol

Bringhen S, Cani L, Antonioli E, Derudas D, Fazio F, Larocca A, Ronconi S, Cellini C, Falcone AP, Accardi F, Liberati AM, Galieni P, Belotti A, Cafro AM, Ria R, Benevolo G, Vincelli ID, Mannina D, Lotti F, Bruno B, Marasco V, Mazza R, Tosi P, Rivolti E, Boccadoro M, D'Agostino M

doi: 10.1016/S2352-3026(25)00162-0

Lymphoma

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201

Leuk Lymphoma

Andreadis C, Bobek O, Hsi ED, Fenske TS, Stiff PJ, Hill BT, Geyer SM, Horwitz M, Khimani F, Little RF, Dinner SN, Friedberg JW, Kahl BS, Perales MA, Devine SM, Leonard JP, Bartlett NL

doi: 10.1080/10428194.2025.2525982

Further Publications

Busulfan Once versus Four Times daily: Impact on Pharmacokinetics, Organ Toxicities and Survival After Allogeneic Hematopoietic Stem Cell Transplantation

Transplant Cell Ther

Seydoux C, Passweg JR, Heim D, Halter J, Rentsch KM, Medinger M

doi: 10.1016/j.jtct.2025.04.019

Lung, Respiratory and Thoracic Cancer

First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial

Lung Cancer

Lee KH, Lee JS, Sugawara S, Kang JH, Kim HR, Inui N, Hida T, Yoshida T, Tanaka H, Yang CT, Inoue T, Nishio M, Ohe Y, Tamura T, Yamamoto N, Yu CJ, Akamatsu H, Takahashi S, Nakagawa K

doi: 10.1016/j.lungcan.2025.108109

Leukemia

Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study From the Société Francophone de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC)

Am J Hematol

Chalandon Y, Devillier R, Boumendil A, Nguyen S, Bulabois CE, Ceballos P, Brissot E, Rubio MT, Labussière-Wallet H, Maertens J, Chevallier P, Maillard N, Poiré X, Castilla-Llorente C, Beguin Y, Cornillon J, Maury S, Marchand T, Daguindau E, Bay JO, Turlure P, Joris M, Menard AL, Bilger K, Guillerm G, François S, Bazarbachi A, Chantepie S, Lewalle P, Marçais A, Loschi M, Benakli M, Chauvet P, Forcade E, Huynh A, Robin M, Masouridi-Levrat S

doi: 10.1002/ajh.27701

Head and Neck Cancer

Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trial

CA Cancer J Clin

Tang LL, Chen L, Xu GQ, Zhang N, Huang CL, Li WF, Mao YP, Zhou GQ, Lei F, Chen LS, Huang SH, Chen L, Chen YP, Zhang Y, Liu X, Xu C, Zhao Y, Li JB, Liu N, Xie FY, Guo R, Sun Y, Ma J

doi: 10.3322/caac.21881

Leukemia

Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM Trial

Haematologica

Balduzzi A, Glogova E, Peters C, Sedlacek P, Dalle JH, Locatelli F, Meisel R, Burkhardt B, Buechner J, Wachowiak J, Bierings M, Staciuk R, Graphakos S, Güngör T, Yesilipek A, Svec P, Palma J, Krivan G, Diaz-de-Heredia C, Limido F, Ansari M, Kalwak K, Bader P, Ifversen M

doi: 10.3324/haematol.2025.287456

Genitourinary Cancer

First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial

Lancet Oncol

Zhou A, Shen P, Li J, Qu W, Wang Z, Ren X, Li Y, Jiang S, Li G, Zeng Y, Qin W, Wu J, Chen P, Zhou F, Guo H, Ji Z, Wang Y, He Z, Wu J, Shi B, Liu L, Yao X, Ma L, Liu Z, Gou X, Fu B, Wang S, Jiang K, Chong T, Tu X, Zhang X, Yu D, Rexiati M, Xue X, Fei J, Wan J, Jia L, He Y, Cui T, Yang AQ, Guo J, Sheng X

doi: 10.1016/S1470-2045(25)00343-2

Related content